Bristol Myers Squibb (CELG-RI) Current Taxes (2009 - 2019)
Bristol Myers Squibb (CELG-RI) posted quarterly Current Taxes of $525.0 million for Q1 2019, up 77.36% year-over-year from $296.0 million in Q1 2018, and up 31.91% quarter-over-quarter from $398.0 million in Q4 2018.
Bristol Myers Squibb (CELG-RI) Current Taxes (2009 - 2019) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Current Taxes for 11 consecutive years, with $525.0 million the latest figure, recorded in Q1 2019.
- In Q1 2019, Current Taxes rose 77.36% year-over-year to $525.0 million; the TTM figure through Mar 2019 stood at $525.0 million (up 77.36% YoY), while the FY2018 annual figure was $398.0 million, up 72.29% from the prior year.
- Current Taxes climbed to $525.0 million in Q1 2019 per CELG-RI's latest filing, from $398.0 million in the prior quarter.
- Across five years, Current Taxes topped out at $572.0 million in Q4 2015 and bottomed at $98.0 million in Q2 2015.
- Historically, Current Taxes has averaged $295.9 million across 5 years, with a median of $291.0 million in 2017.
- Annual changes were most pronounced in 2015 — Current Taxes soared 118.32% — and 2016, when it slumped 73.43%.
- Bristol Myers Squibb's Current Taxes stood at $572.0 million in 2015, then plunged by 73.43% to $152.0 million in 2016, then jumped by 51.97% to $231.0 million in 2017, then surged by 72.29% to $398.0 million in 2018, then soared by 31.91% to $525.0 million in 2019.
- Business Quant data shows CELG-RI's Current Taxes at $525.0 million in Q1 2019, $398.0 million in Q4 2018, and $355.0 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.08 Bn | 633.32 Bn | 17.26 Bn | 1.05 Bn |
| 2 | AbbVie | 470.80 Bn | 464.23 Bn | 12.70 Bn | - |
| 3 | Merck | 377.96 Bn | 370.82 Bn | 12.21 Bn | 4.22 Bn |
| 4 | Novartis Ag | 303.49 Bn | 295.80 Bn | 11.24 Bn | 2.31 Bn |
| 5 | Astrazeneca | 257.97 Bn | 253.07 Bn | 12.86 Bn | 1.47 Bn |
| 6 | Amgen | 236.98 Bn | 222.99 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.41 Bn | 179.23 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.49 Bn | 147.79 Bn | 10.94 Bn | 653.00 Mn |
| 9 | Gsk | 106.28 Bn | 102.11 Bn | 8.24 Bn | -703.04 Mn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 525.00 Mn |
| Dec 31, 2018 | 398.00 Mn |
| Sep 30, 2018 | 355.00 Mn |
| Jun 30, 2018 | 373.00 Mn |
| Mar 31, 2018 | 296.00 Mn |
| Dec 31, 2017 | 231.00 Mn |
| Sep 30, 2017 | 213.00 Mn |
| Jun 30, 2017 | 291.00 Mn |
| Mar 31, 2017 | 180.00 Mn |
| Dec 31, 2016 | 152.00 Mn |
| Sep 30, 2016 | 312.00 Mn |
| Jun 30, 2016 | 164.00 Mn |
| Mar 31, 2016 | 472.00 Mn |
| Dec 31, 2015 | 572.00 Mn |
| Sep 30, 2015 | 179.00 Mn |
| Jun 30, 2015 | 98.00 Mn |
| Mar 31, 2015 | 220.00 Mn |
| Dec 31, 2014 | 262.00 Mn |
| Sep 30, 2014 | 312.00 Mn |
| Jun 30, 2014 | 204.00 Mn |